Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Hutchmed China Ltd ADR (HCM)

Hutchmed China Ltd ADR (HCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket FinancialNewsMedia - Fri Oct 4, 8:15AM CDT

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END

ONCY : 0.9920 (-0.30%)
BGNE : 189.72 (+1.08%)
HCM : 16.83 (+0.54%)
ABBV : 165.89 (-0.23%)
ONC.TO : 1.39 (+0.72%)
ELVN : 25.22 (+1.29%)
FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket Newswire.ca - Fri Oct 4, 8:00AM CDT

/CNW/ -- USA News Group News Commentary – While some forms of cancer are seeing death rates fall, the world is witnessing a global surge in cancers among...

ONCY : 0.9920 (-0.30%)
BGNE : 189.72 (+1.08%)
HCM : 16.83 (+0.54%)
ABBV : 165.89 (-0.23%)
ONC.TO : 1.39 (+0.72%)
ELVN : 25.22 (+1.29%)
Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004 Globe Newswire - Tue Aug 9, 2022

SAN DIEGO and SHANGHAI, China and HONG KONG, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited...

HCM : 16.83 (+0.54%)
HCM.LN : 264.860 (-0.05%)
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial Globe Newswire - Mon Aug 8, 2022

— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase...

HCM : 16.83 (+0.54%)
HCM.LN : 264.860 (-0.05%)
HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer Globe Newswire - Sun Aug 7, 2022

— Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile — — Plans for...

HCM : 16.83 (+0.54%)
HCM.LN : 264.860 (-0.05%)
HUTCHMED Reports 2022 Interim Results and Provides Business Updates Globe Newswire - Mon Aug 1, 2022

Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE®, SULANDA® and ORPATHYS® growth First presentation of SAVANNAH data...

HCM : 16.83 (+0.54%)
HCM.LN : 264.860 (-0.05%)
HUTCHMED Initiates a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China Globe Newswire - Mon Aug 1, 2022

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today...

HCM : 16.83 (+0.54%)
HCM.LN : 264.860 (-0.05%)
HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China Globe Newswire - Fri Jul 15, 2022

HMPL-A83 is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and its second large molecule drug candidate to enter...

HCM : 16.83 (+0.54%)
HCM.LN : 264.860 (-0.05%)
HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting Globe Newswire - Tue Jul 12, 2022

— 49% ORR amongst SAVANNAH patients with higher MET levels —...

HCM : 16.83 (+0.54%)
HCM.LN : 264.860 (-0.05%)
Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007 Globe Newswire - Tue Jul 5, 2022

SAN DIEGO and SHANGHAI and HONG KONG and SYDNEY, Australia, July 06, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED...

HCM : 16.83 (+0.54%)
HCM.LN : 264.860 (-0.05%)

Barchart Exclusives

After Underperforming in 2024, is Mega-Cap Microsoft Stock Still a Buy? Barchart - 20 minutes ago
MSFT has underperformed the markets this year, but analysts still like the stock. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot